TABLE 2.

Thirty-day all-cause mortality risks in the propensity score-matched cohort

Variablea	Unadjusted HR (95% CI)	P	aHRb (95% CI)	P
Male sex	1.71 (0.92–3.18)	0.090	0.91 (0.43–1.91)	0.80
E. coli	0.26 (0.13–0.49)	<0.0001	0.38 (0.17–0.83)	0.015
Nosocomial acquisition	4.26 (2.28–7.94)	<0.0001	2.68 (1.32–5.42)	0.006
Underlying disease
Liver cirrhosis	2.98 (1.25–7.10)	0.014	1.76 (0.58–5.37)	0.32
ESRD	4.47 (1.08–18.56)	0.039	1.87 (0.28–12.57)	0.52
Solid tumor, localized	2.82 (1.49–5.35)	0.002	1.96 (0.93–4.11)	0.077
Metastatic solid tumor	5.42 (2.83–10.39)	<0.0001	3.96 (1.28–12.24)	0.017
Chemotherapy within 6 mo	3.26 (1.59–6.67)	0.001	1.27 (0.47–3.44)	0.64
CCI	1.35 (1.20–1.53)	<0.0001	1.03 (0.85–1.25)	0.75
Source of infection		<0.0001		0.45
Urinary tract	Reference		Reference
Biliary	2.09 (0.75–5.81)	0.16	1.42 (0.45–4.43)	0.55
Other	5.30 (2.70–10.44)	<0.0001	1.73 (0.74–4.05)	0.21
Pitt bacteremia score	1.29 (1.09–1.51)	0.003	1.29 (1.06–1.56)	0.012
Severe sepsis or septic shock	3.78 (1.67–8.55)	0.001	3.14 (1.30–7.59)	0.011
Carbapenem
Other carbapenem	Reference		Reference
Ertapenem	0.59 (0.31–1.11)	0.10	0.60 (0.29–1.22)	0.16

^aESRD, end-stage renal disease.

^bVariables with P values of <0.20 in univariate analyses were included in adjusted analyses.